From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.
Commentary|Articles|June 1, 2026
Experts Weigh In on Finerenone's Priority Review for CKD in Type 1 Diabetes
Fact checked by: Ron Panarotti
With no new kidney-protective therapies approved in T1D for over 3 decades, experts break down the clinical significance of finerenone's FDA priority review and what pharmacists need to know.
Advertisement
Advertisement
For more than 3 decades, patients with type 1 diabetes (T1D) and chronic kidney disease (CKD) have had few to no new therapeutic options specifically designed to slow kidney disease progression. That could soon change. The FDA has accepted a supplemental new drug application (sNDA) and granted priority review to finerenone (Kerendia; Bayer) for the treatment of adults with T1D and CKD, a regulatory milestone that experts say could reshape how clinicians approach this historically undertreated population.1
Related to this article
Jai Radhakrishnan, MD, MBBS, MS, FASN, discusses why IgG4-related kidney disease is often missed and what the MITIGATE subgroup data presented at ASN Kidney Week 2026 show.
October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
Real-world data from ASN Kidney Week show GLP-1 RA users with CKD and obesity had lower rates of kidney failure, death, and heart failure exacerbation.
Hiddo J. L. Heerspink, PharmD, PhD, discusses SOLSTICE elecoglipron data, finerenone in FSGS, and glucagon’s kidney effects from ASN Kidney Week 2026.
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.
Advertisement
Advertisement